$1.26 Billion is the total value of Palo Alto Investors LP's 32 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $167,528,000 | -1.9% | 1,976,265 | -4.1% | 13.25% | -11.0% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $132,649,000 | -11.3% | 633,534 | -0.2% | 10.49% | -19.6% |
| INSM | INSMED INC | $125,802,000 | +9.2% | 5,840,398 | 0.0% | 9.95% | -0.9% | |
| ABMD | Sell | ABIOMED INC | $120,559,000 | -1.5% | 490,754 | -0.7% | 9.53% | -10.6% |
| RVNC | REVANCE THERAPEUTICS INC | $118,936,000 | +95.4% | 4,405,039 | 0.0% | 9.40% | +77.2% | |
| FOLD | AMICUS THERAPEUTICS INC | $102,811,000 | -2.8% | 9,847,774 | 0.0% | 8.13% | -11.8% | |
| PRTA | Sell | PROTHENA CORP PLC | $100,026,000 | +119.1% | 1,649,777 | -1.9% | 7.91% | +98.8% |
| BIIB | BIOGEN INC | $96,382,000 | +30.9% | 360,981 | 0.0% | 7.62% | +18.8% | |
| STAA | Sell | STAAR SURGICAL CO | $77,385,000 | -1.4% | 1,096,882 | -0.9% | 6.12% | -10.6% |
| SAGE | SAGE THERAPEUTICS INC | $33,341,000 | +21.2% | 851,409 | 0.0% | 2.64% | +10.0% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $30,694,000 | +21.1% | 5,621,533 | 0.0% | 2.43% | +9.8% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $27,455,000 | +16.1% | 1,678,196 | 0.0% | 2.17% | +5.3% | |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $21,402,000 | -21.2% | 2,166,156 | -13.0% | 1.69% | -28.5% |
| GOSS | GOSSAMER BIO INC | $20,973,000 | +43.1% | 1,750,651 | 0.0% | 1.66% | +29.8% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $14,721,000 | +24.9% | 612,600 | 0.0% | 1.16% | +13.3% | |
| ALKS | ALKERMES PLC | $13,474,000 | -25.0% | 603,400 | 0.0% | 1.06% | -32.0% | |
| ANAB | ANAPTYSBIO INC | $10,995,000 | +25.7% | 431,024 | 0.0% | 0.87% | +13.9% | |
| ALGN | ALIGN TECHNOLOGY INC | $9,176,000 | -12.5% | 44,305 | 0.0% | 0.73% | -20.6% | |
| EHTH | Buy | EHEALTH INC | $7,734,000 | -49.9% | 1,977,993 | +19.5% | 0.61% | -54.5% |
| GRTS | GRITSTONE ONCOLOGY INC | $5,989,000 | +6.2% | 2,330,504 | 0.0% | 0.47% | -3.7% | |
| KZR | KEZAR LIFE SCIENCES INC | $5,650,000 | +4.1% | 656,200 | 0.0% | 0.45% | -5.5% | |
| CYTK | CYTOKINETICS INC | $5,413,000 | +23.3% | 111,717 | 0.0% | 0.43% | +11.7% | |
| CLVS | CLOVIS ONCOLOGY INC | $5,324,000 | -33.9% | 4,473,967 | 0.0% | 0.42% | -40.0% | |
| TVTX | TRAVERE THERAPEUTICS INC | $4,092,000 | +1.7% | 166,069 | 0.0% | 0.32% | -7.7% | |
| PRVB | New | PROVENTION BIO INC | $1,759,000 | – | 390,800 | +100.0% | 0.14% | – |
| MIRM | MIRUM PHARMACEUTICALS INC | $1,359,000 | +7.9% | 64,700 | 0.0% | 0.11% | -2.7% | |
| ALIMERA SCIENCES INC | $1,021,000 | -7.1% | 200,919 | 0.0% | 0.08% | -15.6% | ||
| ALDX | ALDEYRA THERAPEUTICS INC | $859,000 | +33.8% | 160,800 | 0.0% | 0.07% | +21.4% | |
| MGTA | MAGENTA THERAPEUTICS INC | $610,000 | +17.5% | 432,300 | 0.0% | 0.05% | +6.7% | |
| TCMD | TACTILE SYSTEMS TECHNOLOGY I | $211,000 | +6.6% | 27,100 | 0.0% | 0.02% | 0.0% | |
| MARINUS PHARMACEUTICALS INC | $208,000 | +36.8% | 31,330 | 0.0% | 0.02% | +23.1% | ||
| URGN | UROGEN PHARMA LTD | $204,000 | +1.5% | 24,500 | 0.0% | 0.02% | -11.1% | |
| NVAX | Exit | NOVAVAX INC | $0 | – | -12,500 | -100.0% | -0.06% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -6,774,541 | -100.0% | -0.87% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biomarin Pharmaceuticals, Inc | 42 | Q3 2023 | 16.6% |
| UNITED THERAPEUTICS CORP DEL | 42 | Q3 2023 | 15.3% |
| INSMED INC | 42 | Q3 2023 | 14.1% |
| STAAR Surgical Company | 42 | Q3 2023 | 11.8% |
| AMICUS THERAPEUTICS INC | 42 | Q3 2023 | 12.1% |
| VANDA PHARMACEUTICALS INC | 42 | Q3 2023 | 5.8% |
| PROTHENA CORP PLC | 42 | Q3 2023 | 9.1% |
| CYTOKINETICS INC | 40 | Q3 2023 | 0.4% |
| ALIGN TECHNOLOGY INC | 39 | Q3 2023 | 2.5% |
| ABIOMED INC | 38 | Q3 2022 | 17.1% |
View Palo Alto Investors LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALIMERA SCIENCES INCSold out | April 03, 2023 | 0 | 0.0% |
| Epizyme, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| INSMED Inc | February 14, 2023 | 5,871,291 | 4.3% |
| Vanda Pharmaceuticals Inc. | February 14, 2023 | 1,087,064 | 1.4% |
| ALIMERA SCIENCES INC | February 14, 2022 | 802,423 | 11.6% |
| Clovis Oncology, Inc. | February 14, 2022 | 3,997,826 | 3.1% |
| STAAR SURGICAL CO | February 14, 2022 | 1,140,511 | 2.4% |
| Aimmune Therapeutics, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| AMAG PHARMACEUTICALS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| ALIMERA SCIENCES INC | February 14, 2020 | 802,424 | 16.2% |
View Palo Alto Investors LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-04-03 |
| 4 | 2023-03-28 |
View Palo Alto Investors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.